🧫
Brain Connectivity-Targeted tACS Trial in Early AD
active
experiment
Created: 2026-04-02T05:18:40
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-wiki-brain-connectivity-tacs-early-a
🧫 Experiment Protocol
ClinicalAlzheimer's DiseaseMCIhuman postmortem brain tissue (middle temporal gyrus)proposed
# Brain Connectivity-Targeted tACS Trial in Early AD
## Background and Rationale
Alzheimer's disease (AD) represents a complex neurodegenerative disorder characterized not only by the hallmark pathological accumulations of amyloid-beta plaques and tau neurofibrillary tangles, but increasingly recognized for its profound disruption of neural network function. Emerging evidence from resting-state functional magnetic resonance imaging (rs-fMRI) studies reveals that early-stage AD is marked by aberrant hyperconnectivity within the default mode network (DMN), a critical brain network involved in self-referential processing and memory consolidation. This network dysfunction appears to precede significant structural brain changes and may serve as a mechanistic driver facilitating the trans-synaptic propagation of pathological tau protein throughout interconnected brain regions. The hyperconnectivity observed in early AD likely reflects compensatory mechanisms attempting to maintain cognitive function amid underlying pathological processes, but ultimately becomes maladaptive and accelerates disease progression.
This innovative study employs transcranial alternating current stimulation (tACS) as a non-invasive neuromodulation technique to directly target and normalize aberrant network connectivity patterns in transgenic mouse models of early-stage Alzheimer's disease. The experimental approach is grounded in the principle that tACS can entrain neural oscillations at specific frequencies, thereby modulating functional connectivity within targeted brain networks. By applying individualized stimulation protocols based on each animal's baseline connectivity profile, this intervention aims to restore physiological network dynamics and interrupt the pathological cascade of tau propagation. The use of 5-6 month old transgenic mice represents an optimal temporal window for intervention, as this age corresponds to established amyloid pathology but precedes extensive tau accumulation and neuronal loss.
The experimental design integrates cutting-edge neuroimaging techniques with molecular neuropathology assessment to comprehensively evaluate therapeutic efficacy. Baseline characterization includes rs-fMRI to map individual connectivity patterns, Morris water maze testing for cognitive function assessment, and immunohistochemical analysis of tau pathology distribution. The tACS intervention protocol involves daily 20-minute sessions using frequencies specifically calibrated to each animal's DMN oscillatory patterns, typically targeting gamma (30-100 Hz) or theta (4-8 Hz) ranges known to be disrupted in AD. Post-intervention assessments will employ the same multimodal approach to quantify changes in network connectivity, tau propagation patterns, and cognitive performance, with particular attention to the integrity of hippocampal-cortical circuits critical for memory formation.
The significance of this research extends beyond its immediate therapeutic implications, as it addresses fundamental questions about the relationship between network dysfunction and protein pathology in neurodegeneration. Success in demonstrating that targeted neuromodulation can both normalize connectivity patterns and reduce tau propagation would provide crucial proof-of-concept for network-based therapeutic strategies in AD. This approach represents a paradigm shift from traditional pharmacological interventions targeting individual proteins toward systems-level interventions addressing circuit dysfunction. The findings could inform the development of personalized neuromodulation protocols for human AD patients and establish connectivity-based biomarkers for treatment response monitoring.
This experiment directly tests predictions arising from the following hypotheses:
- **Gamma entrainment therapy to restore hippocampal-cortical synchrony**
- **Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation**
- **Prefrontal sensory gating circuit restoration via PV interneuron enhancement**
- **Sleep Spindle-Synaptic Plasticity Enhancement**
- **HCN1-Mediated Resonance Frequency Stabilization Therapy**
## Experimental Protocol
Step 1: Recruit a cohort of transgenic AD mice (5-6 months old) with confirmed early-stage amyloid pathology, randomly assigning them to tACS intervention and control groups. Establish baseline neurophysiological and cognitive assessments using Morris water maze and resting-state fMRI. Step 2: Apply targeted transcranial alternating current stimulation (tACS) at individualized network-specific frequencies determined by each mouse's baseline functional connectivity patterns, with 20-minute daily sessions over 8 weeks. Use precision electrode placement guided by high-resolution neural mapping to target default mode network regions. Step 3: Conduct comprehensive longitudinal assessments measuring synaptic connectivity, tau propagation, neuroinflammatory markers, and cognitive performance at 4-week intervals during intervention.
## Expected Outcomes
1. Measurable reduction in functional hyperconnectivity within default mode network regions by 25-30% compared to control group. 2. Decreased rate of tau protein accumulation and aggregation in targeted brain regions. 3. Improvement in spatial memory and cognitive performance metrics on standardized neuropsychological tests.
## Success Criteria
1. Statistically significant (p<0.05) reduction in network hyperconnectivity compared to untreated transgenic controls. 2. Demonstrate at least 40% reduction in pathological tau propagation between connected brain regions. 3. Maintain neuronal health with less than 10% neuronal loss in intervention group.
PRIMARY OUTCOME
cellular population changes across AD progression phases
EXPECTED OUTCOMES
## EXPECTED OUTCOMES
**Primary Connectivity Outcomes**
(1) **Default Mode Network Reorganization**: Intervention group demonstrates 25-35% reduction in pathological functional hyperconnectivity within DMN (posterior cingulate cortex to medial prefrontal cortex) by week 8, measured as decreased Pearson correlation coefficient from baseline mean r=0.62±0.08 to post-intervention r=0.42±0.10 (intervention group) versus r=0.59±0.09 (control group, p<0.01 between-group). Regional homogeneity (ReHo) in PCC and medial prefrontal cortex decreases by 18-25% in intervention group, indicating normalization of local overactivity characteristic of early AD pathology. (2) **Hippocampal-Cortical Synchrony Enhancement**: Cross-regional theta coherence (4-8 Hz) between hippocampal CA1 and prefrontal cortex increases by 30-45% in intervention group by week 8 (baseline 0.28±0.06 to post 0.38±0.07) compared to minimal change in controls (0.29±0.05 to 0.31±0.04, p=0.003 interaction). Hippocampal-cortical gamma phase-locking value increases by 20-30% during active exploration tasks, supporting enhanced information integration. (3) **Sleep-Dependent Plasticity Restoration**: Spontaneous sleep spindle density increases 40-50% in intervention group (baseline 8.2±1.3 spindles/minute NREM sleep to 12.1±1.8, p=0.002), with corresponding spindle-associated slow-wave sleep enhancement by 15-20%. Spindle amplitude shows 25-35% increase, correlating with hippocampal-cortical theta coherence improvements.
**Pathological Biomarker Outcomes**
(4) **Tau Propagation Attenuation**: CSF phosphorylated tau (pTau181) concentration in hippocampus decreases by 35-45% in intervention group by week 8 (baseline 285±42 pg/mL to 165±38 pg/mL) versus 8-12% reduction in controls (baseline 290±45 to 265±48 pg/mL, p<0.001 between-group). Immunohistochemical quantification shows 40-50% reduction in hyperphosphorylated tau burden in CA1-CA3 pyramidal layers and prefrontal cortex layers II/III in intervention animals. Tau seeding potential (measured via tau bioassay in hippocampal lysates) diminishes by 45-55% compared to controls. (5) **Neuroinflammatory Modulation**: Pro-inflammatory cytokine levels (IL-6, TNF-α) in hippocampal CSF decrease 30-40% by week 8 in intervention group (IL-6: 125±18 to 78±12 pg/mL, p=0.001), with reduced microglial activation (Iba1+ cell density -25% and ramified morphology restored in 60-70% of profiled cells). IL-10 (anti-inflammatory) increases 35-50% in intervention group, indicating polarization toward neuroprotective M2 phenotype.
**Synaptic and Neuronal Integrity Outcomes**
(6) **Synaptic Preservation and Plasticity**: Synaptophysin+ puncta density increases 20-30% in hippocampal CA1 stratum radiatum in intervention group versus 5-8% in controls (baseline ~450 puncta/100 µm² to ~560 in intervention, p=0.004). PSD-95 intensity increases 25-35%, indicating post-synaptic density stabilization. Dendritic spine density in CA1 pyramidal neurons increases 15-25% in intervention group (baseline 1.8±0.3 to 2.2±0.3 spines/µm dendrite). Two-photon calcium imaging reveals 30-40% increase in population bursting activity in hippocampal CA1 neuronal ensembles during spatial exploration. (7) **Neuronal Survival**: Neuronal density (NeuN+ cells) declines only 6-9% from baseline in intervention group by week 12, versus 18-22% decline in control mice (p=0.006 between-group), indicating robust neuroprotection. Apoptotic marker (active caspase-3) is 45-55% lower in intervention group in PFC and hippocampus.
SUCCESS CRITERIA
## SUCCESS CRITERIA
**Primary Success Criteria (Hierarchical)**
(1) **Network Hyperconnectivity Reduction - Mandatory Threshold**: Achieve statistically significant (p<0.05, two-tailed t-test with Bonferroni multiple comparisons correction across 12 DMN seed regions) between-group difference in default mode network functional connectivity by week 8. Specific target: posterior cingulate cortex - medial prefrontal cortex Pearson correlation coefficient reduction of ≥25% in intervention group (absolute reduction ≥0.15 correlation units) compared to controls with <8% change. This criterion must be met to proceed with claim of efficacy; failure requires protocol re-evaluation. Validation criterion: effect size Cohen's d ≥0.85 for between-group comparison.
(2) **Tau Propagation Attenuation - Mandatory Threshold**: Demonstrate ≥40% reduction in phosphorylated tau (pTau181 or pTau217) concentration in hippocampal CSF (microdialysate) measured at weeks 8-12 in intervention group compared to control group baseline-adjusted trajectories (p<0.01, repeated-measures ANOVA with group×time interaction, corrected for multiple comparisons across 4 timepoints). This must be corroborated by immunohistochemistry showing ≥40% reduction in hyperphosphorylated tau (AT8+ or pS396-tau+) burden in CA1-CA3 pyramidal layer relative to controls (quantified by blinded stereological point-counting across 3 coronal sections per animal, 8 animals per group minimum). Combined effect size must exceed d ≥0.90 across biomarkers.
(3) **Neuronal Integrity Preservation - Mandatory Threshold**: Maintain neuronal density loss to <10% in intervention group compared to age-matched AD transgenic controls at week 12 endpoint. Criterion operationalized as: (a) NeuN+ cell counts in hippocampus (CA1-CA3 combined) and medial prefrontal cortex (layers II/III) decline ≤8% from baseline to week 12 in intervention group versus ≥18% decline in controls (p=0.006, independent-samples t-test), (b) active caspase-3+ apoptotic cells reduced by ≥50% in intervention versus controls, (c) electron microscopy ultrastructure analysis showing preservation of synaptic integrity (synaptic cleft width 18-22 nm, normal presynaptic vesicle density ≥30 vesicles/100 nm² in ≥85% of quantified synapses in intervention group versus <65% in controls).
**Secondary Success Criteria (Supporting Evidence)**
(4) **Cognitive Performance Improvement**: Morris water maze escape latency improvement of ≥20% in intervention group by week 8 (baseline 35±8 seconds to ≤28±6 seconds) with maintained performance through week 16, compared to progressive deterioration in controls (baseline 36±7 to 48±9 seconds, p=0.008, two-way repeated-measures ANOVA). Object recognition discrimination index in intervention group improves to ≥0.55 (chance=0.50) by week 8, versus <0.52 in controls.
(5) **Sleep Architecture Normalization**: Increase spontaneous sleep spindle density by ≥40% in intervention group (baseline 8.2±1.3 to ≥11.5 spindles/minute NREM sleep) measured via electrocorticography, with effect maintained at week 16 (p<0.01). Spindle-fast oscillation coupling strength increases ≥30% in intervention group, quantified via wavelet-based time-frequency analysis.
(6) **Cross-Regional Coherence Enhancement**: Hippocampal-cortical theta coherence (4-8 Hz) increases ≥30% in intervention group versus <10% in controls (p=0.003, interaction effect). Gamma phase-locking value between hippocampus and prefrontal cortex increases ≥25% during active exploration in intervention group.
(7) **Microglial Phenotype Shift**: Ramified microglial morphology restored in ≥65% of Iba1+ cells in intervention group versus <40% in controls (p=0.004). Pro-inflammatory/anti-inflammatory cytokine ratio (IL-6+TNF-α/IL-10) decreases ≥35% in intervention group CSF by week 8.
**Failure Criteria - Protocol Termination Thresholds**
(8) **Safety Endpoint**: Intervention discontinued if ≥2 animals experience seizure activity, unexplained mortality, or ≥20% body weight loss. Any electrode-related infection or intracranial hemorrhage detected via MRI mandates individual animal removal and device re-assessment. Study halted if adverse event frequency exceeds 15% in intervention group.
(9) **Efficacy Futility**: If primary criterion #1 (network connectivity reduction) shows between-group p-value >0.20 at week 8 interim analysis (n=12/group), protocol undergoes revision or termination as per pre-specified futility rules. If tau reduction criterion #2 shows <15% reduction in intervention group by week 8, alternative stimulation parameters must be tested with formal amendment.
PROTOCOL
## PROTOCOL
**Phase 1: Pre-intervention Characterization and Baseline Assessment (Weeks -4 to 0)**
Recruit a cohort of 48 transgenic AD model mice (APP/PS1 or 5xFAD line, 5-6 months old, n=24 intervention, n=24 controls) with confirmed early-stage amyloid-beta pathology validated via in vivo two-photon microscopy and plasma biomarkers (phospho-tau181, phospho-tau217). Perform comprehensive baseline neurophysiological profiling including: (1) resting-state functional magnetic resonance imaging (rs-fMRI) at 9.4T with 200 µm isotropic resolution to map default mode network (DMN) connectivity patterns, (2) electrophysiological recordings from prefrontal cortex (PFC), hippocampal CA3-CA1, and posterior cingulate cortex (PCC) using 32-channel silicon probes to characterize baseline oscillatory dynamics and cross-regional coherence in theta (4-12 Hz), gamma (30-100 Hz), and sleep spindle (10-16 Hz) bands, (3) Morris water maze testing for spatial reference memory (acquisition: 4 days, 6 trials/day; probe trial on day 5), (4) object recognition task for non-spatial memory assessment, (5) immunohistochemical quantification of amyloid burden and tau hyperphosphorylation in PFC, hippocampus, and entorhinal cortex from terminal biopsies in subset (n=8/group). Establish individual frequency response profiles by applying broadband electrical stimulation (1-100 Hz sweeps) to DMN nodes and measuring evoked local field potential responses to identify resonance peaks for each subject.
**Phase 2: Network-Targeted tACS Intervention Protocol (Weeks 1-8)**
Implement precision transcranial alternating current stimulation using custom-designed dual-electrode arrays implanted epidurally over medial prefrontal cortex and posterior cingulate cortex based on high-resolution magnetic resonance imaging co-registration with stereotaxic atlas coordinates (bregma: AP +1.8mm/-4.2mm, ML ±0.5mm). Stimulation parameters calibrated to individual baseline connectivity profiles: frequency range 8-12 Hz (theta-alpha band, chosen based on Phase 1 resonance profiling); current amplitude 50-100 µA (intensity-matched to evoke ~0.5-1.0 mV peak-to-peak field potentials in target regions); symmetrical biphasic pulse waveform (1 ms per phase); 20-minute daily sessions (1400-1500 hours, circadian-standardized) for 5 consecutive days per week over 8 weeks. Control group receives sham stimulation (electrode implantation identical, zero current delivery). Concurrent polysomnographic monitoring via high-density electrocorticography (16-channel array) to track spontaneous sleep architecture, spindle activity, and slow-wave sleep duration as surrogate markers of tACS-induced neural plasticity. Real-time impedance monitoring and stimulation parameter adjustment to maintain consistent current delivery within ±5% variation.
**Phase 3: Longitudinal Outcome Quantification (Weeks 4, 8, 12, and 16 post-intervention onset)**
Conduct assessments at 4-week intervals during intervention and 4 weeks post-cessation: (1) Repeat rs-fMRI with identical acquisition parameters to quantify dynamic connectivity changes within DMN (seed-based correlation analysis of PCC-medial prefrontal cortex connectivity, threshold r >0.3); (2) Electrophysiological recordings measuring hippocampal-cortical theta coherence, prefrontal gamma power (40-100 Hz) during active exploration, and sleep spindle density/amplitude; (3) Behavioral testing: Morris water maze (3 trials/day, 2 days/week), object recognition (inter-trial interval 24 hours), novel object location task, Y-maze spontaneous alternation; (4) Cerebrospinal fluid (CSF) biomarker quantification via microdialysis from hippocampus: phosphorylated tau (pTau181, pTau217), total tau, amyloid-beta 42, inflammatory cytokines (IL-6, TNF-α, IL-1β) measured by multiplexed immunoassay; (5) Immunofluorescence analysis of PV+ interneuron density, synaptic marker intensity (synaptophysin, PSD-95), and activated microglial morphology in 40-µm sagittal sections from perfusion-fixed brains (n=6/group/timepoint); (6) Two-photon microscopy imaging of GCaMP6f-expressing neurons in hippocampal CA1 (256×256 µm field-of-view, 512×512 pixel resolution, 30 Hz frame rate) to quantify neuronal population activity patterns and calcium event frequency during open-field exploration.
LINKED HYPOTHESES
h-bdbd2120· Gamma entrainment therapy to restore hippocampal-cortical synchronyh-856feb98· Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservationh-62f9fc90· Prefrontal sensory gating circuit restoration via PV interneuron enhancementh-8d270062· Sleep Spindle-Synaptic Plasticity Enhancementh-d40d2659· HCN1-Mediated Resonance Frequency Stabilization Therapy
Source: wiki
🧫 Experiment Extras
ESTIMATED COST
$520,000
TIMELINE
18 months
PATHWAY
neuroinflammation, myelination, neuronal loss
MARKET PRICE
$0.46
STATUS
proposed
Scoring Dimensions
Prerequisite Graph (1 upstream, 2 downstream)
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.